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Background
Glutathione S-transferase P1 (GSTP1), the abundant isoform of glutathione S-trans-
ferases (GSTs) in lung epithelium, plays an important role in cellular protection against
oxidative stress and toxic foreign chemicals. It has been suggested that polymor-
phisms in the GSTP1 gene are associated with asthma and related phenotypes. As
significant interindividual and interethnic differences exist in the distribution of xeno-
biotic-metabolizing enzymes, we have studied the GSTP1 Ile105Val polymorphism in
patients with asthma in a Turkish sample.
Methods
GSTP1 Ile105Val polymorphism in exon 5 was determined in 210 patients with
asthma (112 extrinsic and 108 intrinsic) and 265 control individuals without lung
diseases and without history of allergy or atopy, using polymerase chain reaction
(PCR)-restriction fragment length polymorphism (RFLP) techniques.
Results
The proportion of GSTP1 Val105 homozygotes was significantly lower in the patients
with asthma than in the control individuals (3.8% vs 12.1%). The odds ratio for
GSTP1 Val105 homozygotes vs all other genotypes was 0.29 (95%CL 0.13–0.64, p
= 0.01) for asthmatics. The distribution of GSTP1 Ile105Val genotypes and the
frequency of GSTP1 Val105Val homozygotes (3.7% vs 3.9%) was not significantly
different between extrinsic and intrinsic asthmatics.
Conclusion
These results suggest a significant association between GSTP1 Ile105Val polymor-
phism and susceptibility to asthma and that the GSTP1 Val105Val genotype may be
protective against developing this disease.
Introduction
Asthma is a chronic disease characterised by reversible
airflow obstruction and airway inflammation that affects
many people all over the world with increasing morbid-
ity and mortality, especially in developed countries [1].
The pathogenesis and aetiology of asthma is very com-
plex and not fully understood, although an interaction
of multiple genetic loci and a variety of environmental
factors have been suggested as important determinants
of this disease [2, 3].
Some of the many potential candidate genes that may
be associated with asthma include receptor genes, such
as the beta 2-adrenergic receptor [4], genes encoding
proinflammatory cytokines (the interleukin-13 (IL-13)
gene) as well as their receptors (IL-4R alpha) [5], genes
involved in signal transduction, such as the human sig-
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nal transducer and activator of transcription 6 (STAT6)
[6, 7]. Furthermore, some studies have shown an asso-
ciation between asthma and polymorphisms of enzymes
that play an important role in the biotransformation of
exogenous and endogenous compounds, such as hista-
mine N-methyltransferase [8] and N-acetyltransferase 2
[9, 10]. In addition, polymorphisms of glutathion S-
transferase (GST) members have been suggested as
individual susceptibility factors to lung diseases [11].
The predominant cytosolic GST expressed in the human
lung, GSTP1, is a candidate gene, because of its role in
cellular protection against oxidative stress. Recently, it
has been shown that a valine (Val) to isoleucine (Ile)
exchange at codon 105 (GSTP1 Val105/Val105) in exon
5 may protect against developing asthma [12–16].
Although the Val105 variant has higher catalytic effi-
ciency for polycyclic aromatic hydrocarbon diol
epoxides, its efficiency for 1-chloro-2,4-dinitrobenzene
is lower compared to the Ile105 variant [17, 18].
This study was performed to find out whether the
GSTP1 Ile105Val polymorphism had an impact on sus-
ceptibility to bronchial asthma, classified as in the
intrinsic and extrinsic asthmatics of a Turkish sample.
Method
Subjects
The study population consisted of 210 consecutive bron-
chial asthma patients (108 diagnosed as extrinsic and
102 as intrinsic asthmatics; 156 female, 54 male; mean
age 40.1 years; range 17–70 years), genotyped for N-
acetyltransferase 2 (NAT2) acetylation status in a recent
study [10], and 265 control individuals (184 female, 81
male: mean age 42.3 years; range 20–73 years) residing
around Gaziantep, in South-East Anatolia, Turkey.
There was no gender or age differences between the two
groups (P = 0.214 and p = 0.619, respectively). Both
groups were comparable in terms of ethnicity. Active
smokers were excluded. All individuals gave written
informed consent and the study was approved by the
local ethics committee of the University of Gaziantep.
The patients were unrelated atopic and nonatopic asth-
matic outpatients of the Department of Pulmonology,
Sahinbey Hastanesi, Gaziantep, Turkey. The diagnosis
was based on medical history, physical examination,
lung function tests and chest X-rays, skin ‘prick’ tests,
and total immunglobulin E (IgE) level. The diagnostic
criteria used to establish asthma definition was the pro-
tocol of The European Community Respiratory Health
Survey (ECRHS) [19]. Patients showing at least one
skin prick test positivity were defined as extrinsic asth-
matics. Control individuals were selected from staff
members of the Medical Faculty of Gaziantep and out-
patients of other Departments of our Hospital without
signs and symptoms of asthma and other lung diseases,
and allergy or atopy on the basis of questionnaire
responses.
Total IgE and prick test assays
Total IgE were determined by immulite® (Diagnostic
Products Corporotion (DPC), C.A (USA) which is a
chemiluminescent enzyme-labelled qualitative immu-
noassay technique (normal range 1.0–183 IU ml-1). We
have used Stallargenes-Pasteur allergen extracts includ-
ing Dermatophagoides pteronyssinus, Alternaria, Cla-
dosporium, cat epithelia, Olea europea, Parietaria
officinalis and Phleum pratense for the prick test. The
negative control contained phenolated glycerol-saline
solution and the positive control histamine solution of
1 mg ml-1. The results of the prick test were considered
to be positive if the diameters of the indurations of both
histamine and allergens were the same.
Identification of GSTP1 genotypes
DNA was extracted from leucocytes manually by stan-
dard 3-step phenol/chloroform extraction and stored at
+4 ∞C until further analysis. GSTP1 genotypes were
determined by two previously described polymerase
chain reaction restriction-fragment length polymor-
phism (PCR-RFLP) analyses [18, 20]. No direct
sequencing was performed. Briefly, 176 and 329 base
pair (bp) fragments containing the Ile105Val polymor-
phism site were digested by Alw26I (New England
Biolabs, Schwalbach, Germany) for two hours at 37 ∞C
and the RFLP products were separated by 3.5% agarose
gel electrophoresis.
Statistics
The differences in GSTP1 genotype and allele frequen-
cies between patient and control groups were examined
with the Chi-square and Fisher’s two-sided exact test.
The analysis were performed using SPSS program Ver-
sion 10.1 (Chicago, Illinois, USA). P-values of <0.05
were considered to be statistically significant.
Results
Using  the  two  PCR-RFLP  methods  for  determining
the GSTP1 Ile105Val polymorphism, all genotypes
were identically determined without discrepant results.
The frequency of GSTP1 Val105 homozygotes was
found significantly lower in the group of patients with
asthma than in the control individuals (3.8% vs 12.1%,
p = 0.01) (Table 1). The odds ratio for GSTP1 Val105Val
homozygotes vs all other genotypes was 0.29 (95%CL
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GSTP1 Genotypes n % n % OR 95%CL P
Ile105Ile 55 50.9 54 53.0 1 _
Ile105Val 49 45.4 44 43.1 1.09 0.63–1.89 > 0.05
Val105Val 4 3.7 4 3.9 0.94 0.23–3.87 > 0.05
GSTP1 Alleles
A (Ile) 159 73.6 152 74.5 1 _
G (Val) 57 26.4 52 25.5 0.95 0.62–1.48 > 0.05
Table 2
Distribution of GSTP1 genotypes and 
alleles among patients with extrinsic and 
intrinsic asthma
0.13–0.64, p = 0.01) for asthmatics. In addition, the
odds ratio for GSTP1 Val105 homozygotes vs Ile105
homozygotes was 0.31 (95%CL 0.14–0.69, p = 0.03) for
asthma patients, whereas no statistically significant dif-
ference was detected between heterozygote asthmatics
and control subjects. The distribution of GSTP1
Ile105Val genotypes and the frequency of GSTP1
Val105Val homozygotes (3.7% vs 3.9%) was not signif-
icantly different between extrinsic and intrinsic asthmat-
ics (Table 2). However, the total number of asthmatics
homozygous for the mutant allele was small. There
was no statistically significant difference of GSTP1
allele distribution between asthma patients and control
subjects as well as between extrinsic and intrinsic
asthmatics.
Discussion
The production of reactive oxygen species (ROS) by
several inflammatory cells, which participate in airway
inflammation, may contribute to the epithelial damage
of asthmatic airways [21]. Furthermore, genetic poly-
morphisms of xenobiotic-metabolizing enzymes leading
to interindividual differences in the formation of protein
adducts may result in a different susceptibility to chem-
ically induced allergy and autoimmunity [22]. Thus,
defects in detoxifying ROS may influence the develop-
ment and severity of asthma. It has been proposed that
GSTP1 is a candidate enzyme in protecting the epithe-
lial cells against ROS and related toxic products [12,
13].
Indeed, polymorphisms of the GSTP1 gene have been
associated with susceptibility to lung diseases, including
chronic obstructive pulmonary disease (COPD) and
asthma and related phenotypes [12–16, 23]. Recently,
it has been found that the presence of the GSTP1
Val105Val genotype conferred a sixfold lower risk of
asthma compared to the wild type GSTP1 Ile105Ile
genotype and that the frequency of GSTP1 Val105Val
genotype correlated negatively with severity of airway
dysfunction [12].
In the present study, we have also found an associa-
tion between the GSTP1 Ile105Val polymorphism and
susceptibility to asthma in a Turkish sample consisting
of 210 asthma patients classified as extrinsic and intrin-
sic asthmatics. As the prevalence of cigarette smoking







GSTP1 Genotypes n % n % OR 95%CL P
Ile105Ile 109 51.9 134 50.6 1 _
Ile105Val 93 44.3 99 37.4 1.15 0.79–1.69 0.46
Val105Val 8 3.8 32 12.1 0.31 0.14–0.69 0.03
GSTP1 Alleles
A (Ile) 311 74.0 367 69.2 1 _
G (Val) 109 26.0 163 30.8 0.79 0.59–1.05 0.10
Table 1
Frequencies of GSTP1 genotypes among 
asthmatics and control subjects and 
association of GSTP1 genotypes with 
asthma risk
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excluded active smokers to avoid potential confounding
factors such as smoking habits. The frequency of
GSTP1 Val105 homozygotes  was  significantly  lower
in  patients with asthma than in control individuals
(3.8% vs 12.1%, p = 0.01) and the odds ratio for GSTP1
Val105 homozygotes vs Ile105 homozygotes was 0.31
(95%CL 0.14–0.69, p = 0.03). In addition, the frequency
of GSTP1 Val105Val homozygotes was not significantly
different between extrinsic and intrinsic asthmatics
(3.7% vs 3.9%), suggesting that the GSTP1 Val105Val
genotype is protective not only of allergic asthma, but
also of nonatopic, nonallergic asthma. However, it
should be considered that, although these two major
types of asthma could be distinguished according to
disease onset, patient and family history, epidermal
prick test, IgE levels, and allergen dependency, there is
a wide overlap between extrinsic and intrinsic asthma.
On the other hand, both allergic and nonallergic stimuli
may lead to epithelial cell inflammatory response, which
is an important biochemical feature of asthma [25].
Therefore, it seems to be possible that GSTP1 plays a
role in allergic as well as nonallergic asthma subtypes
by modulation of ROS production.
In conclusion, our results demonstrate a significant
association between Ile105Val polymorphism in exon
5 of GSTP1 and susceptibility to asthma and that the
GSTP1 Val105Val genotype might protect against
developing this disease. Whilst the Ile105Val polymor-
phism may contribute but little to the asthma pheno-
type, it is possible that other polymorphisms such as
the Ala114Val substitution in exon 6 might be
relevant.
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